Option chain shows key data for Valneva's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Valneva.

Valneva (NASDAQ:VALN) Stock, Option Chain

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

bz_pharma_briefs

Biotech

News

Health Care

Movers

Trading Ideas

General

VALN

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Accenture- AI Advantage

Intraday Update

Markets

INOD

MESO

MVST

OMER

PRTA

SHCO

TRIP

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

Consistent Symptoms

Equities

Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.

Valneva&#39;s Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults

Valneva SE

Press Releases

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Contracts

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Earnings

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences

PARIS:VLA

PARIS:VLAP

Abivax

Altimmune

AnaptysBio

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Chimerix

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Sionna Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tyra Biosciences

Verve Therapeutics

HC Wainwright & Co.

Guggenheim

Comments

Valneva

Valneva (VALN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga